Home > Insider Trading > Filing (0001062993-23-018622)

Filing Details

Accession Number:: 0001062993-23-018622
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-29 17:54:02
Reporting Period:: 2023-09-29

Accepted Time:: 2023-09-29 17:54:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1042074	Cymabay Therapeutics Inc.	CBAY	Pharmaceutical Preparations (2834)	943103561

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1252524	Von Kurt Emster	C/O Cymabay Therapeutics, Inc. 7575 Gateway Blvd., Suite 110 Newark CA 94560		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-29	15,921	$5.00	105,921	No	4	M	Direct
Common Stock	Disposition	2023-09-29	15,921	$15.68	90,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-09-29	6,357	$0.00	6,357	$5.00
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-09-29	943	$0.00	943	$5.00
Common Stock	Stock Appreciation Right	Disposition	2023-09-29	3,372	$0.00	3,372	$5.00
Common Stock	Employee Stock Option (right to buy)	Disposition	2023-09-29	5,249	$0.00	5,249	$5.00

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2023-10-30	No	4	M	Direct
2023-12-22	No	4	M	Direct
2023-12-22	No	4	M	Direct
2024-01-05	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	18,406	Indirect	By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 30, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $15.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This corrects a typographical error made in the reporting person's previous Form 4 filings. In filings between October 2, 2017 and March 17, 2018 (inclusive) the reporting person reported 17,236 shares held indirectly rather than the 17,326 shares that the reporting person actually held indirectly (and had reported previously). After adding 1,080 shares on June 5, 2018 the reporting person incorrectly reported in a filing on June 7, 2018 and in filings thereafter owning 18,316 shares indirectly rather than the 18,406 shares that the reporting person actually held indirectly.
The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.
The option vested as to 1/4 of the underlying shares on April 2, 2010 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
The incentive award (the "Award") was granted under the CymaBay 2013 Equity Incentive Plan and could be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The shares subject to the Award vested in 48 equal monthly installments from the grant date.
The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.